Eloxx Pharmaceuticals Stock EBITDA
| ELOXDelisted Stock | USD 6.12 0.30 4.67% |
Eloxx Pharmaceuticals fundamentals help investors to digest information that contributes to Eloxx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eloxx Pink Sheet. The fundamental analysis module provides a way to measure Eloxx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eloxx Pharmaceuticals pink sheet.
Eloxx |
Eloxx Pharmaceuticals Company EBITDA Analysis
Eloxx Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Eloxx Pharmaceuticals EBITDA | (34.42 M) |
Most of Eloxx Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eloxx Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Eloxx Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (34.42 Million). This is 103.92% lower than that of the Pharmaceuticals sector and 134.37% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.88% higher than that of the company.
Eloxx EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eloxx Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eloxx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eloxx Pharmaceuticals by comparing valuation metrics of similar companies.Eloxx Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Eloxx Fundamentals
| Return On Equity | -6.15 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 30.28 M | ||||
| Shares Outstanding | 2.75 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 37.06 % | ||||
| Number Of Shares Shorted | 21.48 K | ||||
| Price To Earning | (7.94) X | ||||
| Price To Book | 6.31 X | ||||
| EBITDA | (34.42 M) | ||||
| Net Income | (36.06 M) | ||||
| Cash And Equivalents | 30.05 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 13.38 M | ||||
| Current Ratio | 1.62 X | ||||
| Book Value Per Share | (7.46) X | ||||
| Cash Flow From Operations | (31.84 M) | ||||
| Short Ratio | 0.20 X | ||||
| Earnings Per Share | (12.93) X | ||||
| Target Price | 55.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 2.68 | ||||
| Market Capitalization | 14.86 M | ||||
| Total Asset | 21.12 M | ||||
| Retained Earnings | (274.39 M) | ||||
| Working Capital | (2.96 M) | ||||
| Current Asset | 3.84 M | ||||
| Current Liabilities | 840.05 K | ||||
| Z Score | -23.07 | ||||
| Net Asset | 21.12 M |
About Eloxx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eloxx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eloxx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eloxx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Eloxx Pink Sheet
If you are still planning to invest in Eloxx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eloxx Pharmaceuticals' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |